O11 biomedical
| Invested since | 2023 |
| Based in | North Rhine-Westphalia |
About the company
O11 biomedical, a visionary medical technology start-up that emerged as part of BioTex at RWTH Aachen University/ University Hospital Aachen 2022, aims to improve survival rates and quality of life for patients struggling with severe respiratory distress. O11 has developed a disruptive therapy that allows patients to “breathe out” carbon dioxide via the intestines, freeing them from hours of agonizing ventilation therapy: RESPILIQ™. With currently 6 employees and its own production and development facility in Aachen, O11 is ideally positioned for the future.
Do you want to
know more about this company?
More startups from Life Sciences
CustomSurg, founded in 2021, is a Spin-Off from ETH Zurich and Harvard University. The company is developing software-as-a-medical-device (SaMD) solutions for the optimal selection and placement of orthopaedic implants in …
To the complete profileof CustomSurg
NovaPump GmbH is developing and realising a leading solution for a novel right ventricular assist device (RVAD) with clear USPs (the only percutaneous device with pulsatile support). NovaPump’s catheter-based heart …
To the complete profileof NovaPump
Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …
To the complete profileof Lindis Blood Care
Exit
Research, development and marketing of high-precision laser-based endoscopic and microscopic measuring systems for different application of minimal invasive surgery. Our products intend to make surgical interventions safer while optimizing costs.
To the complete profileof Scopis
Exit
adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species. Antibody …
To the complete profileof adivo
Exit
Humedics markets a system for bedside and instantaneous measurement of liver function. Patented device, consumables and a diagnostic drug allow an optimal market offering.
To the complete profileof Humedics